These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Josting A; Wiedenmann S; Franklin J; May M; Sieber M; Wolf J; Engert A; Diehl V; J Clin Oncol; 2003 Sep; 21(18):3440-6. PubMed ID: 12668650 [TBL] [Abstract][Full Text] [Related]
5. Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome. Martínez-Climent JA; Comes AM; Vizcarra E; Benet I; Arbona C; Prósper F; Solano C; García Clavel B; Marugán I; Lluch A; García-Conde J Bone Marrow Transplant; 2000 Jun; 25(11):1203-8. PubMed ID: 10849534 [TBL] [Abstract][Full Text] [Related]
6. Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies. Park S; Brice P; Noguerra ME; Simon D; Rousselot P; Kerneis Y; Morel P; Marolleau JP; Gisselbrecht C Bone Marrow Transplant; 2000 Aug; 26(3):321-6. PubMed ID: 10967573 [TBL] [Abstract][Full Text] [Related]
7. Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation. Abdelhameed A; Pond GR; Mitsakakis N; Brandwein J; Chun K; Gupta V; Kamel-Reid S; Lipton JH; Minden MD; Schimmer A; Schuh A; Yee K; Messner HA Cancer; 2008 Apr; 112(7):1513-21. PubMed ID: 18286528 [TBL] [Abstract][Full Text] [Related]
8. Physician Education: Myelodysplastic Syndrome. Yoshida Y Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004 [TBL] [Abstract][Full Text] [Related]
9. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773 [TBL] [Abstract][Full Text] [Related]
10. The incidence of secondary leukemias. Leone G; Mele L; Pulsoni A; Equitani F; Pagano L Haematologica; 1999 Oct; 84(10):937-45. PubMed ID: 10509043 [TBL] [Abstract][Full Text] [Related]
11. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies. Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466 [TBL] [Abstract][Full Text] [Related]
12. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome. Beran M Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661 [TBL] [Abstract][Full Text] [Related]
13. [Study on the transformation from myelodysplastic syndromes into acute leukemias]. Shi J; Shao Z; Liu H; Li K; Song L; Zhang Y; Zheng Y; Chen G; Chu Y; He H; Zhao M; He G; Feng B; Hao Y; Yang T; Yang C Zhonghua Xue Ye Xue Za Zhi; 2001 Jul; 22(7):351-4. PubMed ID: 11877096 [TBL] [Abstract][Full Text] [Related]
14. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578 [TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Kantarjian H; Beran M; Cortes J; O'Brien S; Giles F; Pierce S; Shan J; Plunkett W; Keating M; Estey E Cancer; 2006 Mar; 106(5):1099-109. PubMed ID: 16435387 [TBL] [Abstract][Full Text] [Related]
16. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
17. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727 [TBL] [Abstract][Full Text] [Related]
18. [Myelodysplastic syndrome: a review]. Creutzig U; Hoelzer D Klin Padiatr; 1987; 199(3):169-72. PubMed ID: 3626418 [TBL] [Abstract][Full Text] [Related]
19. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Brown JR; Yeckes H; Friedberg JW; Neuberg D; Kim H; Nadler LM; Freedman AS J Clin Oncol; 2005 Apr; 23(10):2208-14. PubMed ID: 15753460 [TBL] [Abstract][Full Text] [Related]
20. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]